Apogee Therapeutics Inc.
Apogee Therapeutics Announces 2024 Full Year Results and Positive Phase 1 Data for APG990
Summary
On March 3, 2025, Apogee Therapeutics, Inc. reported its full-year 2024 financial results and announced positive interim Phase 1 results for APG990. The company reported a cash position of $731.1 million as of December 31, 2024, and highlighted progress across its pipeline, including the initiation of the Phase 2 APEX clinical trial for APG777 and the planned Phase 1b trial for APG279. The company also announced it will host a webcast to discuss the Phase 1 data results for APG990.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement